Explore
Validate
Learn
Immunocytochemistry
Chromatin ImmunoprecipitationAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Chromatin Immunoprecipitation [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- HPA003128 - Provider product page
- Provider
- Atlas Antibodies
- Proper citation
- Atlas Antibodies Cat#HPA003128, RRID:AB_1078745
- Product name
- Anti-EP300
- Antibody type
- Polyclonal
- Description
- Polyclonal Antibody against Human EP300, Gene description: E1A binding protein p300, Alternative Gene Names: KAT3B, p300, Validated applications: IHC, ICC, ChIP, Uniprot ID: Q09472, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 100 µl
- Concentration
- 0.3 mg/ml
- Storage
- Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Handling
- The antibody solution should be gently mixed before use.
Submitted references RNF168 facilitates oestrogen receptor ɑ transcription and drives breast cancer proliferation
Identification of the SOX2 Interactome by BioID Reveals EP300 as a Mediator of SOX2-dependent Squamous Differentiation and Lung Squamous Cell Carcinoma Growth
Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer.
Liu Z, Zhang J, Xu J, Yang H, Li X, Hou Y, Zhao Y, Xue M, Wang B, Yu N, Yu S, Niu G, Wu G, Li X, Wang H, Zhu J, Zhuang T
Journal of Cellular and Molecular Medicine 2018;22(9):4161-4170
Journal of Cellular and Molecular Medicine 2018;22(9):4161-4170
Identification of the SOX2 Interactome by BioID Reveals EP300 as a Mediator of SOX2-dependent Squamous Differentiation and Lung Squamous Cell Carcinoma Growth
Kim B, Coyaud E, Laurent E, St-Germain J, Van de Laar E, Tsao M, Raught B, Moghal N
Molecular & Cellular Proteomics 2017;16(10):1864-1888
Molecular & Cellular Proteomics 2017;16(10):1864-1888
Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer.
Asaduzzaman M, Constantinou S, Min H, Gallon J, Lin ML, Singh P, Raguz S, Ali S, Shousha S, Coombes RC, Lam EW, Hu Y, Yagüe E
Breast cancer research and treatment 2017 Jun;163(3):461-474
Breast cancer research and treatment 2017 Jun;163(3):461-474
No comments: Submit comment
Supportive validation
- Submitted by
- Atlas Antibodies (provider)
- Main image
- Experimental details
- ChIP-Exo-Seq composite graph for Anti-EP300 (HPA003128, Lot A95516) tested in K562 cells. Strand-specific reads (blue: forward, red: reverse) and IgG controls (black: forward, grey: reverse) are plotted against the distance from a composite set of reference binding sites. The antibody exhibits robust target enrichment compared to a non-specific IgG control and precisely reveals its structural organization around the binding site. Data generated by Prof. B. F. Pugh´s Lab at Cornell University.
